Home > Insider Trading > Filing (0001225208-10-019874)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1405197	Talecris Biotherapeutics Holdings Corp.	TLCR	Pharmaceutical Preparations (2834)	202533768

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1472088	E Joel Abelson	4101 Research Commons 79 T.w. Alexander Drive Research Triangle Park NC 27709	Sr Vp & Gm, Int'l Bus.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-08-25	105,440	$11.00	119,489	No	4	M	Direct
Common Stock	Disposition	2010-08-25	105,440	$21.89	14,049	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Options (right to buy)	Disposition	2010-08-25	105,440	$11.00	105,440	$11.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2007-04-01	2016-12-06	No	4	M	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Options (right to buy)	$19.00		2019-09-30	11,755	11,755	Direct
Common Stock	Options (right to buy)	$11.00	2009-04-01	2018-04-01	186,360	186,360	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2019-09-30	11,755	11,755	Direct
2018-04-01	186,360	186,360	Direct

Footnotes

The transaction reported was effected purusant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2010.
The number of shares reported includes restricted share units representing the right to receive 5,921 shares of the Issuers common stock that will vest in three equal annual installments beginning April 1, 2011, as detailed in a restricted share unit award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.81 to $21.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The option is fully vested and immediately exercisable.
Option will vest in three equal annual installments beginning April 1, 2011, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.